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Introduction
Tumor invasion with subsequent metastases is the major
cause of morbidity and mortality in patients with cancer.
For patients with breast cancer, the development of
metastases is the most important prognostic factor, as
almost all patients with distant metastasis succumb to the
disease [1–3].
Numerous studies have linked aberrant expression of
E-cadherin with the development of metastases in breast
cancer and other cancers. E-cadherin is a transmembrane
glycoprotein that mediates calcium-dependent intercellular
adhesion and is specifically involved in epithelial cell-to-
cell adhesion [4–6]. The E-cadherin gene, located on
chromosome 16q22.1, is an important regulator of mor-
phogenesis [7,8]. In cancer, decreased E-cadherin
expression is one of the alterations that characterizes the
invasive phenotype, and the data support its role as a
tumor suppressor gene [9–12]. Studies have shown that
aberrant E-cadherin expression is associated with the
acquisition of invasiveness and more advanced tumor
stage for many cancers including lung cancer [13],
prostate cancer [14,15], gastric cancer [16], colorectal
carcinoma [17], and breast cancer [18–20].
Normal ductal epithelial cells in the mammary gland
strongly express E-cadherin protein in the cytoplasmic
membrane [21,22]. Some studies in breast cancer have
ER = estrogen receptor; PR = progesterone receptor.
Available online http://breast-cancer-research.com/content/5/6/R217
Research article
E-cadherin expression in primary carcinomas of the breast and
its distant metastases
Paul J Kowalski1, Mark A Rubin2 and Celina G Kleer1
1Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA
2Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Correspondence: Celina G Kleer (e-mail: kleer@umich.edu)
Received: 1 Jul 2003   Revisions requested: 14 Aug 2003   Revisions received: 18 Aug 2003   Accepted: 22 Aug 2003   Published: 26 Sep 2003
Breast Cancer Res 2003, 5:R217-R222 (DOI 10.1186/bcr651)
© 2003 Kowalski et al., licensee BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X). This is an Open Access article: verbatim
copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original
URL.
Abstract
Introduction Aberrant expression of E-cadherin has been
associated with the development of metastases in patients with
breast cancer. Even though the expression of E-cadherin has
been studied in primary breast tumors, little is known about its
expression at the distant metastatic sites. We investigate the
relationship between E-cadherin expression in primary breast
carcinoma and their distant, non-nodal metastases.
Methods Immunohistochemical analysis of E-cadherin was
performed in tissues from 30 patients with primary invasive
breast carcinoma and their distant metastases. E-cadherin
expression was evaluated as normal or aberrant (decreased
when compared with normal internal positive controls, or absent).
Results Twenty-two (73%) invasive carcinomas were ductal,
and eight (27%) were lobular. Of the primary invasive ductal
carcinomas, 55% (12/22) had normal E-cadherin expression
and 45% (10/22) had aberrant expression. All of the
metastases expressed E-cadherin with the same intensity as
(12 tumors) or with stronger intensity than (10 tumors) the
corresponding primaries. Of the invasive lobular carcinomas,
one of eight (12%) primary carcinomas and none of the
metastases expressed E-cadherin in the cell membranes, but
they accumulated the protein in the cytoplasm.
Conclusion Aberrant E-cadherin expression is frequent in
invasive ductal carcinomas that progress to develop distant
metastases. Distant metastases consistently express
E-cadherin, often more strongly than the primary tumor. Invasive
lobular carcinomas have a different pattern of E-cadherin
expression, suggesting a different role for E-cadherin in this
form of breast carcinoma.
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demonstrated that aberrant E-cadherin expression is asso-
ciated with high-grade, estrogen receptor (ER)-negative,
and metastatic breast carcinomas, whereas other studies
have failed to confirm these findings [22–24]. In the
present article, we set out to determine and compare the
expression patterns of E-cadherin in primary breast carci-
nomas and their distant, non-nodal metastases.
Materials and methods
Patient selection
Thirty patients with breast cancer who developed distant
metastases were identified using a computerized data-
base. Breast tissues from the primary carcinoma and the
corresponding distant, non-nodal metastases were
retrieved from the Surgical Pathology files in our institu-
tion, with Institutional Review Board approval.
We identified 30 cases of primary invasive breast carcino-
mas and 32 cases of distant metastases (two patients
each had two metastatic sites). Hematoxylin and eosin
stained slides were available for review in all cases.
Primary invasive carcinomas were measured microscopi-
cally, and were classified as invasive ductal carcinoma,
invasive lobular carcinoma or other special types accord-
ing to well-accepted criteria [25,26]. A histologic grade
was assigned to each primary invasive carcinoma [27].
Immunohistochemistry
E-cadherin protein expression was studied by immunohis-
tochemistry using specific monoclonal antibodies against
E-cadherin (HEC-D10; Zymed Laboratories, San Fran-
cisco, CA, USA). For assessment of ER, progesterone
receptor (PR) and HER2/neu expression, specific mono-
clonal antibodies for ER (Ventana Medical Systems,
Tucson, AZ, USA), PR (DAKO, Carpinteria, CA, USA),
and HER2/neu (Herceptest; DAKO) were used following
the manufacturers’ recommended dilutions.
Immunohistochemistry was performed using an automated
immunostainer (Biotek Techmate 500; Ventana Medical
Systems) as described previously [28]. Briefly, 5µm-thick
sections were cut onto glass slides from formalin-fixed,
paraffin tissue blocks. Sections were deparaffinized and
were microwaved (1000W Model #MTC1080-2A;
Frigidaire, Dublin, OH, USA) in a pressure cooker (Nordic
Ware, Minneapolis, MN, USA) with 1l of 10mM citrate
buffer (pH6.0). The sections were subsequently cooled
with the lid on for an additional 10 min. After removing the
lid, the entire pressure cooker was filled with cold, running
tap water for 2–3 min or until the slides were cool. At
36°C, the stainer sequentially added an inhibitor of
endogenous peroxidase, the primary antibodies (32 min),
a biotinylated secondary antibody, an avidin–biotin
complex with horseradish peroxidase, 3,3′-diaminobenzi-
dine tetrahydrochloride, and copper enhancer. The slides
were then counter-stained with hematoxylin.
Interpretation of immunohistochemical analysis
E-cadherin expression was interpreted as either normal
(strong) or aberrant (reduced or absent) [29]. Internal pos-
itive controls, such as benign breast lobules and ducts,
were present in most cases. Aberrant staining was
defined as either negative staining or <70% membranous
staining of the population of cells examined. Normal stain-
ing was defined as ≥70% membranous staining of the
cancer cells [29]. The ER and PR were considered posi-
tive when >10% of the tumor cell nuclei were stained. For
HER-2/neu, the strength of the membranous staining was
recorded as 0, 1+ to 3+, and a sample was considered
positive when 10% or more neoplastic cells had a staining
intensity of ≥2+ [30].
Statistical analysis
Differences in percentages of E-cadherin-positive cases
between the primary and metastatic groups were tested
for statistical significance using Fisher’s exact test.
P<0.05 was considered significant. A two-sample t test
was also performed to compare the size, the ER, PR and
HER-2/neu status, and the E-cadherin expression.
Results
Clinical and pathological features
The patients’ characteristics are presented in Table 1. All
patients were female.
The median age at diagnosis of the primary invasive breast
carcinoma was 53.9 years (range, 39–80 years). All primary
tumors were treated by surgical excision. Of the primary
tumors, 22 were invasive ductal carcinomas and eight were
invasive lobular carcinomas. Metastatic sites included the
liver (six cases), the bone marrow (five cases), the skin (four
cases), the lung (three cases), the femoral head (three
cases), the pelvic girdle (two cases), the vertebrae (two
cases), the brain (two cases), the colon (one case), the
ovary (one case), the pericardium (one case), the abdominal
wall (one case), and the contralateral breast (one case).
E-cadherin expression in primary and distant
metastases
Normal breast epithelial cells were used as internal posi-
tive controls for E-cadherin staining in tissue sections. The
glandular epithelium consistently demonstrated unequivo-
cal and strong membranous staining localized at the cell
borders. The nonepithelial components were negative for
E-cadherin protein expression. Of the invasive ductal car-
cinomas, 55% (12/22) had normal E-cadherin expression
and 45% (10/22) had aberrant E-cadherin protein expres-
sion. Of the distant metastases of ductal carcinomas,
70% (16/23) had normal E-cadherin expression and 30%
(7/23) had aberrant expression.
When we compared the staining intensity, all the metasta-
tic cancer cells had E-cadherin expression equal toR219
(13/23) or stronger than (10/23) the corresponding
primary tumors. Figure 1 shows a primary invasive ductal
carcinoma with aberrant E-cadherin expression that devel-
oped a metastasis to the iliac bone expressing normal
levels of E-cadherin (or re-expression). Figure 2 shows
examples of distant metastases of invasive ductal carcino-
mas with normal E-cadherin expression.
All invasive lobular carcinomas (eight cases) showed cyto-
plasmic staining and no protein in the cellular membrane
(Fig.3). Seventy-eight percent (7/9) of metastatic lobular
carcinomas showed E-cadherin protein localized to the
cytoplasm of the tumor cells. The other two metastatic foci
of lobular carcinoma had normal E-cadherin expression
(Table 2). No association was found between E-cadherin
expression in primary invasive ductal carcinomas and the
ER, PR and HER-2/neu status, the histologic grade, and
the tumor size.
Discussion
The expression of E-cadherin in breast cancer metastases
is largely unknown and, to our knowledge, there are no
studies that specifically investigate the expression of
E-cadherin in primary breast carcinomas in relationship to
their distant metastases. We found that aberrant E-cad-
herin expression is a common event in primary invasive
ductal carcinomas that progress to develop distant metas-
tases, as aberrant expression was found in 45% of these
cases.
There is increasing evidence that cancer cells may
re-express E-cadherin protein once they reach distant
sites. We found that all the metastatic deposits from inva-
sive ductal carcinomas expressed E-cadherin, and the
Available online http://breast-cancer-research.com/content/5/6/R217
Figure 1
E-cadherin expression at the primary and distant metastatic sites. (A) and (B) Primary invasive ductal carcinoma with aberrant (reduced) E-cadherin
expression. (C) This tumor metastasized 3 years later to the iliac bone. The metastatic carcinoma cells express normal levels of E-cadherin (re-
expression). 200× magnification.
Figure 2
E-cadherin is expressed at normal levels at the metastatic foci. Distant
metastases from two different primary invasive ductal carcinomas to
(A) the lung and (B) the bone. Note the crisp membranous staining for
E-cadherin, which is specific for the cancer cells. Fibroblasts and other
stromal cells are negative. 200× magnification.
Table 1
Clinical and pathological characteristics
Number of patients 30
Median age (range) (years) 53.9 (39–80)
Pathologic stage at diagnosis [n (%)]
Stage I 3 (10)
Stage II 13 (43.3)
Stage III 6 (20)
Stage IV 2 (6.7)
Tumor size (range) (cm) 2.7 (0.5–7)
Histologic type [n (%)]
Ductal 22 (73)
Lobular 8 (27)
Histologic grade [n (%)]
Grade 1 6 (20)
Grade 2 17 (57)
Grade 3 7 (23)
Lymph node status [n (%)]
Negative 7 (28)
Positive 18 (72)
Estrogen receptor status [n (%)]
Negative 7 (27)
Positive 19 (73)
Progesterone receptor status [n (%)]
Negative 9 (36)
Positive 16 (64)
Median time to develop distant metastases (months)
Ductal 33
Lobular 74degree of expression was either equal to or stronger than
that of the primary tumor. By studying E-cadherin expres-
sion in nodal breast cancer metastases, Bukholm and col-
leagues found that 19 of 20 lymph node metastases
strongly expressed E-cadherin protein [21]. The mecha-
nism and biologic role of E-cadherin re-expression at the
metastatic site has not been elucidated, although it
appears that translational regulation and post-translational
events are probable mechanisms of E-cadherin re-expres-
sion [31].
In order to metastasize, cancer cells must break away from
the primary tumor, move into the surrounding stroma,
intravasate into the circulation, extravasate, and success-
fully re-establish growth at other sites. It is possible that
loss of E-cadherin is a transient phenomenon that allows
malignant cells to invade vascular channels and tissues.
We have previously demonstrated that intralymphatic
breast cancer emboli strongly express E-cadherin protein,
and we postulate that re-expression of E-cadherin occurs
in the circulating tumor cells, enabling the cancer cells to
form tumor emboli and to survive [28]. E-cadherin
re-expression may also enable malignant cells to form a
metastatic deposit by facilitating intercellular adhesion.
The normal expression or re-expression of E-cadherin in
cancer metastases appears to be similar in breast cancer
and prostate cancer. Rubin and colleagues studied a large
group of prostate cancers that included 77 distant metas-
tases and detected normal E-cadherin expression in 90%
of these cases [29].
In breast cancer, a relationship between E-cadherin
expression and ER expression has been noted previously.
ER-positive tumors have been demonstrated to express
normal amounts of E-cadherin protein, and loss of ER and
E-cadherin genes has been linked to disease progression
in invasive carcinomas of the breast. Nass and colleagues
found an association between coincident methylation of
E-cadherin and the ER gene during breast cancer pro-
gression, probably not attributable to coincidence of
methylation for the two genes [32]. In our study, however,
we did not find an association between E-cadherin expres-
sion and the ER, PR or HER-2/neu status.
The role of E-cadherin in the pathogenesis and progres-
sion of invasive lobular carcinoma is intriguing. We found
that all of the primary invasive lobular carcinomas and
nearly all of the metastatic foci had accumulation of E-cad-
herin protein in the cytoplasm of the neoplastic cells, with
no membranous staining. Several studies have demon-
strated that E-cadherin is commonly downregulated in
invasive lobular carcinomas [33–36]. Berx and colleagues
found somatic mutations of the E-cadherin gene in 56%
(27/48 cases) of invasive lobular carcinomas, and 90% of
these tumors had allelic losses at the E-cadherin locus. No
mutations were identified in 50 nonlobular breast cancers
[34]. Sarrio and colleagues recently reported that pro-
moter hypermethylation is another common mechanism of
E-cadherin inactivation in invasive lobular carcinomas,
occurring in 41% (19/46) of cases [36]. De Leeuw and
colleagues reported that 84% (32/38) of invasive lobular
carcinomas had completely absent membranous staining
by immunohistochemistry, and 56% of these cases had
staining in the cytoplasm of the cancer cells [33].
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Figure 3
E-cadherin is accumulated in the cytoplasm of primary and metastatic lobular carcinomas of the breast. (A) and (B) Primary invasive lobular
carcinoma invading fat. Notice the cellular discohesion and vacuolization typical of invasive lobular carcinomas. This tumor has cytoplasmic
accumulation of E-cadherin. (C) Distant metastasis to the liver 8 years later exhibiting the pattern of E-cadherin expression as the primary tumor.
200× magnification.
Table 2
E-cadherin expression in primary invasive carcinomas of the
breast and their distant, non-nodal metastases
Histologic type Total cases Aberrant Normal
Ductal carcinoma
Primary tumor 22 10 (45%) 12 (55%)
Metastases 23 7 (30%) 16 (70%)
Lobular carcinoma
Primary tumor 8 8 (100%) 0
Metastases 9 7 (78%) 2 (12%)The clearly different pattern of E-cadherin expression in
invasive ductal and lobular carcinomas suggests that this
protein may play different roles in the development of each
specific type of tumor. The absence of membranous
E-cadherin expression in invasive lobular carcinomas may
determine the morphologic features such as the charac-
teristic cellular discohesion of the lobular carcinoma cells,
as well as the distinct pattern of stromal invasion of inva-
sive lobular carcinomas, typically as single cells or rows of
cells.
In summary, the present study provides evidence that
approximately one-half of the invasive ductal carcinomas
that develop distant metastases have aberrant E-cadherin
protein expression. E-cadherin is expressed or re-
expressed at the distant metastatic foci of invasive ductal
carcinomas, supporting the hypothesis that re-expression
of E-cadherin may play a role in the establishment of the
metastatic cells at distant sites. Invasive lobular carcino-
mas have a different pattern of E-cadherin expression both
at the primary carcinoma and the metastatic sites, which
suggests a different role for E-cadherin in this form of
breast cancer.
Conclusion
In the present study we specifically determine the expres-
sion of E-cadherin protein in primary invasive carcinomas
and their corresponding distant metastases. We conclude
that E-cadherin is expressed at normal levels at the distant
metastatic site regardless of the level of expression at the
primary invasive ductal carcinoma. This observation may
have biological implications, as re-expression of E-cad-
herin may allow malignant cells to form the metastatic
deposits. Invasive lobular carcinomas have a different
pattern of E-cadherin expression both in the primary tumor
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